Anzeige
Mehr »
Donnerstag, 18.06.2026 - Börsentäglich über 12.000 News
Warum dieser 19M-CAD-Silber-Junior fast 1 Mio. Unzen Gold versteckt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A12FCU | ISIN: US3798941080 | Ticker-Symbol:
Branche
Getränke/Tabak
Aktienmarkt
Sonstige
1-Jahres-Chart
GLUCOSE HEALTH INC Chart 1 Jahr
5-Tage-Chart
GLUCOSE HEALTH INC 5-Tage-Chart
GlobeNewswire (Europe)
59 Leser
Artikel bewerten:
(0)

Glucose Health Inc.: Glucose Health, Inc. (GLUC) Reports Surge in GlucoDown Sales Among two of the Largest Retailers in the National Drug Store Channel

Bentonville, ARKANSAS, June 18, 2026 (GLOBE NEWSWIRE) -- Glucose Health, Inc. (OTCID:GLUC), the maker of GlucoDown®, a scientifically formulated blood sugar support beverage, today announced continued growth and increasing momentum within the national pharmacy channel as demand from two of the largest U.S. pharmacy chains strengthened during the second quarter of 2026.

The Company recently reported a major expansion in retail distribution, with one national pharmacy chain nearly doubling the number of stores carrying GlucoDown® from approximately 1,250 locations to roughly 2,500 locations nationwide. In response to the broader retail footprint, Glucose Health increased its consumer advertising investment during April and May, specifically directing consumers to participating pharmacy locations where GlucoDown® is available.

Glucose Health continues to experience strong year-over-year momentum within the national pharmacy channel, as evidenced by recent sales data. During the first 24 weeks of 2026, the Company shipped more than 120% of the total GlucoDown® volume delivered to a major national pharmacy retailer during all of 2025. Another national drug store chain in the retail pharmacy space has recorded a sales increase of 135.7% for the most recent period from January 1, 2026, through June 6, 2026 versus the same period in 2025. Comparing numbers year-over-year, for the period from August 31, 2025, through June 6, 2026, revenues are up 193%.

Management believes the combination of expanded distribution and targeted consumer marketing is contributing to increased product demand and stronger replenishment orders from retail partners. The company believes that the increase of these two factors serves to underscore increasing demand and accelerating product adoption at retail.

"Our recent results demonstrate a strong relationship between our advertising initiatives and retailer purchasing activity," said Marc Hatch, Chief Operating Officer of Glucose Health. "Creating consumer awareness drives product pull-through at the store level, which in turn generates the reorders that are essential to building a successful national beverage brand."

Chris Jemapete, a Member of the Glucose Health Board of Directors, added: "This level of growth reflects consumers' increasing interest in healthier, functional beverage alternatives. We are encouraged by the positive sales trends we are seeing across two of the largest pharmacy chains in the United States and believe they validate the growing market opportunity for GlucoDown®.

Gerry David, Chairman of the Company's newly created Strategic Board of Advisors, believes GlucoDown® is uniquely positioned to benefit from the growing adoption of GLP-1 medications used for weight management and metabolic health. He noted that "As GLP-1 therapies become increasingly popular, we see a meaningful opportunity for products that complement their benefits," He added that "GlucoDown® is designed to support healthy blood sugar management through its proprietary soluble fiber formulation and can serve as a natural nutritional companion for consumers focused on metabolic wellness."

"Even for GLP-1 users, post-meal glucose fluctuations can occur, particularly as dosages change or individuals transition off treatment," he said. "Clinical research supports the ability of GlucoDown's® soluble fiber ingredient to help moderate post-meal increases in blood glucose levels. "The functional benefits of GlucoDown® are a practical, affordable, food-friendly nutritional tool that supports the same metabolic health goals many GLP-1 users are already pursuing."

Mr. David emphasized that GlucoDown® is not intended to replace GLP-1 therapies but rather to complement them.

GlucoDown® offers a total of 8 great tasting flavors, providing consumers with a variety of choices that includes four "Decaffeinated Tea" flavors Peach, Lemon, Raspberry and Super Berry, as well as four "Enhanced Water" flavors consisting of Peach Mango, Cherry, Watermelon and Strawberry Banana. The four tea flavors were the original product offerings, while the four fruit-flavored water enhanced drink mixes were added later to expand the brand with non-tea options. All GlucoDown® flavors are also gluten free and sugar free and contain only 10 calories per serving.

About Glucose Health, Inc. Glucose Health, Inc. (OTCID:GLUC) is a consumer health and wellness company focused on developing and marketing innovative nutritional products designed to support healthy blood sugar management and metabolic health. The Company's flagship product, GlucoDown®, is a soluble fiber-based beverage formulated to help maintain healthy blood glucose levels as part of a balanced diet and healthy lifestyle.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of federal securities laws. These statements include, but are not limited to, expectations regarding future sales growth, retail expansion, consumer demand, and market opportunities related to GLP-1 therapies. Actual results may differ materially from those projected due to various risks and uncertainties. Investors are encouraged to review the Company's public filings for additional information regarding factors that may affect future results.

This version adopts a more institutional investor-relations tone, tightens the language, improves the flow of the growth story, and presents the GLP-1 discussion in a manner that is more appropriate from a regulatory and public-company communications perspective.

Press Inquiries

Mark Schaftlein
schaftlein [at] juno.com
https://glucodown.com/

A video accompanying this announcement is available here: https://youtube.com/watch?v=ss_cZy4hXik


- - -
© 2026 GlobeNewswire (Europe)
Software vor dem Comeback – diese 5 Aktien könnten durchstarten!
Während Halbleiter- und KI-Infrastrukturwerte von einem Hoch zum nächsten jagen, wurden viele Software-Aktien in den vergangenen Monaten regelrecht aus den Depots gedrängt. Die Angst vor Disruption hat Investoren zu einem radikalen Strategiewechsel veranlasst – mit der Folge, dass zahlreiche Qualitätsunternehmen heute auf Mehrjahrestiefs notieren.

Doch genau hier entsteht eine seltene Chance. Denn während die Bewertungen im Halbleitersektor inzwischen auf ambitionierten Niveaus liegen, ist der Bewertungsabschlag bei Software-Titeln so hoch wie seit Jahren nicht mehr. Gleichzeitig liefern viele Unternehmen weiterhin starke Wachstumszahlen und integrieren KI erfolgreich in ihre Geschäftsmodelle. Die Diskrepanz zwischen Kursentwicklung und operativer Stärke könnte sich schon bald auflösen.

Für Anleger bedeutet das: antizyklisch denken und gezielt zugreifen, bevor der Markt dreht. Denn erste technische Signale deuten darauf hin, dass sich die Trendwende bereits anbahnt.

In unserem aktuellen Spezialreport stellen wir fünf Software-Aktien vor, die besonders aussichtsreich positioniert sind – mit starker Marktstellung, attraktiver Bewertung und hohem Aufholpotenzial.

Jetzt den kostenlosen Report sichern – bevor der Software-Rebound Fahrt aufnimmt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.